4C Biomed
- Biotech or pharma, therapeutic R&D
4C Biomed Limited, based in London, UK with R&D in Netanya, Israel, is an IND-ready immuno-oncology company. Founded as a spin-off from Sheba Hospital, it uses a sensitive screening platform to identify therapeutic targets from ~8,500 genes.
Clinical trials published at ASCO 2024 highlight the potential of the HVEM-BTLA axis. Our lead antibody, anti-4CB1, a first-in-class monoclonal antibody, targets HVEM and blocks both the HVEM-BTLA and HVEM-CD160 interactions, positioning it as a superior competitor to BTLA-targeting therapies. Anti-4CB1 shows promising results, including in-vivo studies with anti-PD1 and enhanced cytotoxicity as a monotherapy in twice as many ex-vivo patient samples as the gold standard anti-PD1, across various solid cancers. Anti-4CB1 is well tolerated, as shown in GLP toxicity studies in cynomolgus monkeys, and is ready for clinical trials.
We seek a licensing deal or $20m Series A funding, with existing investors participating.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}